FABP4 and liver cancer: Moreover, a recent study from Yang et al. proposed the activation of the lipoprotein lipase (LPL)/FABP4/carnitine palmitoyl transferase 1 (CPT1) axis as a direct contributor to liver cancer stem cell trans-differentiation during MASH to hepatocellular carcinoma progression [129].